New Jersey Attorney General Gurbir Grewal last week directed all prosecutors to hold off on trying low-level cannabis crimes as lawmakers work on the language of a legalization measure, the Philadelphia Inquirer reports.

Mind Cure stock is now much more easily accessible for U.S.-based investors.

Numinus’ Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.

Oregon became the first state to legalize psilocybin mushrooms for therapeutic purposes last month, and now the governor is taking initial steps to launch the program by accepting applications for members of an advisory board tasked with figuring out how to best regulate access to the psychedelic treatment.

Voters in New Jersey overwhelmingly approved a marijuana legalization referendum last month, and top lawmakers are already proposing putting cannabis back on the ballot for another vote—but not to undo the reform.

With ATAI eying a Spring 2021 IPO, it announces a $125 million private equity financing for Series C.

Novamind has closed on double its original target (CAD$5 million). Preparing to commence trading on the CSE (symbol “NM”).

ATAI Life Sciences is going public. MindMed Inc is hitting new highs. The two events ARE connected.

Entheon adds a German listing to its original CSE listing.